文献速递肝病消化道肿瘤与早癌

免疫检查点抑制剂治疗癌症患者的乙肝病毒再激活风险

Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-26

这项历史性队列研究纳入2015年1月至2020年9月接受免疫检查点抑制剂(ICI)治疗的3465例癌症患者,评估乙肝病毒(HBV)再激活和肝脏不良事件风险。总体HBV再激活率为0.14%(5/3465),HBsAg阳性患者为1.0%(5/511),HBsAg阴性患者为0.0%(0/2954)。HBsAg阳性患者中,接受抗病毒预防者再激活率为0.4%(2/464),未接受者为6.4%(3/47);无HBV相关死亡。

要点

  • ICI治疗中总体HBV再激活罕见,HBsAg阴性患者未见再激活。
  • HBsAg阳性且未接受抗病毒预防者再激活风险较高(6.4%)。
  • 接受抗病毒预防的HBsAg阳性患者再激活率低(0.4%)。

核心结论

  • 接受ICI治疗且进行抗病毒预防的患者中HBV再激活罕见,但HBsAg阳性未预防或依从性差者可能发生再激活。

研究设计与样本

  • 历史性队列研究,纳入2015年1月至2020年9月接受ICI治疗的3465例癌症患者。

主要发现

  • 总体HBV再激活率为0.14%(5/3465),HBsAg阳性患者为1.0%(5/511),HBsAg阴性患者为0.0%(0/2954)。
  • HBsAg阳性患者中,肝细胞癌患者再激活率为0.5%(2/409),非肝细胞癌患者为2.9%(3/102)。
  • HBsAg阳性患者中,接受抗病毒预防者再激活率为0.4%(2/464),未接受者为6.4%(3/47)。
  • HBsAg阳性患者中3-4级肝炎发生率为4.5%(23例),HBsAg阴性患者为7.4%(218例)。
  • HBsAg阳性患者ICI治疗后HBsAg血清清除仅2例(0.4%),无HBV相关死亡。

临床怎么用

  • 对接受ICI治疗的癌症患者应筛查HBV血清学标志物。
  • HBsAg阳性患者建议接受抗病毒预防并监测依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis B virus (HBV) reactivation is a well-known complication in patients with chronic hepatitis B treated with cytotoxic chemotherapy. However, the risk of HBV reactivation through use of immune checkpoint inhibitors (ICIs) is not well understood. Therefore, we aimed to evaluate the risk of HBV reactivation and hepatic adverse events in patients with cancer receiving ICIs according to cancer type and virologic serology. METHODS: This historical cohort study included 3465 patients with cancer treated with ICIs between January 2015 and September 2020. The primary outcome was the occurrence of HBV reactivation, and the secondary outcome was presence of hepatic adverse events during ICI treatment. RESULTS: The mean patient age was 62.2 years, and 68.8% of patients were men. Of the 3465 eligible patients, 511 (14.7%) showed hepatitis B surface antigen (HBsAg) positivity. The incidence rates of HBV reactivation of the total patients, HBsAg-positive patients, and HBsAg-negative patients were 0.14% (5/3465), 1.0% (5/511), and 0.0% (0/2954), respectively. Among HBsAg-positive patients, HBV reactivation occurred at a rate of 0.5% (2/409) and 2.9% (3/102) in patients with and without hepatocellular carcinoma, respectively. The HBV reactivation rates were 0.4% (2/464) and 6.4% (3/47) in patients with and without antiviral prophylaxis, respectively. Grade 3-4 hepatitis occurred in 23 (4.5%) HBsAg-positive, and 218 (7.4%) HBsAg-negative patients. No HBV-related fatality occurred. Only 2 patients (0.4%) experienced HBsAg seroclearance after ICI treatment among HBsAg-positive patients. CONCLUSIONS: In general, HBV reactivation was rarely observed in patients with antiviral prophylaxis while undergoing ICI treatment. However, HBV reactivation may occur in HBsAg-positive patients without antiviral prophylaxis or noncompliant with antiviral prophylaxis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yoo S, Lee D, Shim JH, et al. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clin Gastroenterol Hepatol. 2021. PMID: 34182151. doi:10.1016/j.cgh.2021.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。